Each film-coated tablet contains: Clopidogrel Bisulfate USP equivalent to Clopidogrel 75 mg.
Pharmacology: Pharmacokinetics: Clopidogrel is rapidly but incompletely absorbed following oral administration; absorption appears to be about 50%. It is a prodrug and is extensively metabolised in the liver following absorption, mainly to the inactive carboxylic acid derivative. The active metabolite appears to be a thiol derivatives but has not been identified in plasma. Clopidogrel and the carboxylic acid derivatives are highly protein-bond. Clopidogrel and its metabolites are excreted about equally in the urine.
Clopidogrel is an analogue of ticlopidine with similar actions. It is given prophylactically as an alternative to aspirin in patients at risk of thromboembolic disorders such as myocardial infarction, peripheral arterial disease and stroke.
Clopidogrel bisulfate should be given as a single daily dose of 75 mg. Or as prescribed by the physician.
Hypersensitivity to the drug. Severe liver impairment. Active pathological bleeding such as peptic ulcer or intracranial haemorrhage.
It should not be administered to patients with haematopoietic disorders such as neutropenia or thrombocytopenia, haemorrhagic diathesis or other haemorrhagic disorders associated with prolonged bleeding time, or conditions with an increased risk of bleeding such as gastrointestinal ulcers, acute cerebral haemorrhage, or severe liver dysfunction.
Blood dyscrasias, including neutropenia and thrombotic thrombocytopenic purpura, and haemorrhagic disorders have also occurred.
Store at temperatures not exceeding 30°C.
B01AC04 - clopidogrel ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Sign Out
